Synthetic a-synuclein fibrils replicate in mice causing MSA-like pathologyShow others and affiliations
2025 (English)In: Nature, ISSN 0028-0836, E-ISSN 1476-4687, Vol. 648, p. 409-417Article in journal (Refereed) Published
Abstract [en]
Multiple-system atrophy (MSA) is a rapidly progressive neurodegenerative disease of unknown cause, typically affecting individuals aged 50-60 years and leading to death within a decade1, 2-3. It is characterized by glial cytoplasmic inclusions (GCIs) composed of fibrillar alpha-synuclein (aSyn)4, 5, 6, 7-8, the formation of which shows parallels with prion propagation9,10. While fibrils extracted from brains of individuals with MSA have been structurally characterized11, their ability to replicate in a protein-only manner has been questioned12, and their ability to induce GCIs in vivo remains unexplored. By contrast, the synthetic fibril strain 1B13,14, assembled from recombinant human aSyn, self-replicates in vitro and induces GCIs in mice15-suggesting direct relevance to MSA-but lacks scrutiny at the atomic scale. Here we report high-resolution structural analyses of 1B fibrils and of fibrils extracted from diseased mice injected with 1B that developed GCIs (1BP). We show in vivo that conformational templating enables fibril strain replication, resulting in MSA-like inclusion pathology. Notably, the structures of 1B and 1BP are highly similar and mimic the fold of aSyn observed in one protofilament of fibrils isolated from patients with MSA11. Moreover, reinjection of crude mouse brain homogenates containing 1BP into new mice reproduces the same MSA-like pathology induced by the parent synthetic seed 1B. Our findings identify 1B as a synthetic pathogen capable of self-replication in vivo and reveal structural features of 1B and 1BP that may underlie MSA pathology, offering insights for therapeutic strategies.
Place, publisher, year, edition, pages
NATURE PORTFOLIO , 2025. Vol. 648, p. 409-417
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:liu:diva-219466DOI: 10.1038/s41586-025-09698-1ISI: 001608151900001PubMedID: 41193804Scopus ID: 2-s2.0-105021048506OAI: oai:DiVA.org:liu-219466DiVA, id: diva2:2014627
Note
Funding Agencies|Swiss National Science Foundation [310030_188548, 10.002.679]; Swiss Parkinson Foundation; Department of Excellence Initiative of the Italian Ministry of Research; Innovative Medicines Initiative 2 Joint Undertaking [116060]; European Union; EFPIA; French Agence Nationale de la Recherche [ANR-21-CE18-0045-03, ANR-22-CE16-0002, ANR-24-CE93-0003]; Fondation pour la Recherche Medicale [MND202411019711]
2025-11-182025-11-182026-01-19